Sept 18 (Reuters) - Crescita Therapeutics Inc
* Crescita Therapeutics reports positive topline results of phase 2 clinical trial for the treatment of plaque psoriasis
* Crescita Therapeutics Inc - trial demonstrated statistical significance in achievement of its primary endpoint
* Crescita Therapeutics Inc - no unanticipated safety signals were noted in the trial
* Crescita - phase 2 results to be evaluated in anticipation of end-of-phase 2 meeting with U.S. FDA to discuss advancement to phase 3
* Crescita Therapeutics Inc - received positive topline results from a phase 2 clinical trial in patients with plaque psoriasis
* Crescita Therapeutics - licensing revenues would be shared between co and partners; co’s share would reflect its contribution of patented formulations Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.